A reader asked me last month whether her serum was “the right one.” It contained kojic acid, alpha-arbutin, and tranexamic acid in some proprietary blend, marketed as a triple-action brightener.
The serum wasn’t wrong, exactly. The marketing was wrong about why.
Kojic acid, alpha-arbutin, and tranexamic acid each appear in dozens of SoC-targeted serums, almost always together, almost always positioned as the natural alternatives to hydroquinone. That framing erases the clinical distinction between them. They share an end goal — less pigment — and target three different points in the melanogenesis cascade. Which one belongs in your protocol depends on whether the pigment is inflammatory, hormonal, or post-procedure. Stacking all three indiscriminately wastes formulation space and sometimes triggers competition for the same skin receptors.
Here’s what each actually does, where the evidence is strongest, and how the stacking decisions work.
Why “hydroquinone alternative” is a marketing category
Hydroquinone is the most-evidenced topical pigment-lightening agent in dermatology. It’s also subject to regulatory scrutiny that’s gotten tighter over the past decade — banned in OTC products by the FDA’s 2020 CARES Act updates in the US, restricted in EU cosmetics, available by prescription in most jurisdictions. The market response was a category of “natural alternative” actives that consumers could buy without a prescription.
Clinically, hydroquinone works by competitive inhibition of tyrosinase, the enzyme that catalyzes the first two steps of melanin synthesis. Most of its alternatives target tyrosinase too, but at different points or by different mechanisms. A few target downstream steps. Calling them all “hydroquinone alternatives” implies functional equivalence that doesn’t hold up clinically.
Kojic acid — tyrosinase inhibition with a ceiling
Kojic acid is a chelating agent derived from Aspergillus fungi. It binds the copper ions at tyrosinase’s active site, competitively inhibiting the enzyme. The mechanism is well-characterized — Lee’s 2015 review (J Cosmet Dermatol) covers the binding chemistry in detail.
Clinically, kojic acid has solid evidence at 1-2% topical concentrations. Most efficacy data comes from combination protocols (kojic + glycolic acid + hydroquinone has been studied repeatedly for melasma) rather than monotherapy. As a standalone OTC active at 1-2%, expect modest improvement over 12-16 weeks for epidermal pigment.
The concentration ceiling matters. Above 2-3%, kojic acid becomes meaningfully irritating, particularly in Fitzpatrick IV-VI skin, where the irritation can trigger PIH and net-negative the brightening benefit. The 4% high-strength kojic serums are formulation choices that almost always cross the irritation tipping point.
Kojic acid also oxidizes rapidly when exposed to air and light. Most kojic acid serums you’ll find in clear bottles on store shelves have already lost meaningful activity. Brown bottles, airless pumps, or stabilizer combinations (kojic acid dipalmitate is more stable than free kojic acid) matter clinically.
Alpha-arbutin — slower, gentler, fewer side effects
Alpha-arbutin is a glycosylated derivative of hydroquinone. In the skin, it slowly hydrolyzes back to hydroquinone, releasing it gradually rather than delivering a bolus dose. The release kinetics give alpha-arbutin a different clinical profile: slower onset (8-12 weeks vs. 4-8 for hydroquinone), gentler side effect profile, and accumulating evidence at concentrations of 1-3%.
Boissy and colleagues’ 2005 work (Exp Dermatol) characterized the mechanism. The clinical translation: alpha-arbutin is the right choice when patient tolerance is the dominant constraint and time-to-result is flexible. It’s a reasonable option for sensitive SoC patients who can’t tolerate either hydroquinone or higher-concentration kojic acid.
The trade-off is potency. Alpha-arbutin’s evidence for active melasma is weaker than hydroquinone or tranexamic acid. For maintenance — preventing pigment recurrence after a fade course — it’s defensible. For active pigment that needs to come down quickly, it’s underpowered.
Tranexamic acid — the melasma-specific tool
Tranexamic acid (TXA) is a plasmin inhibitor originally developed as an oral antifibrinolytic for surgical and obstetric hemorrhage. Its dermatological applications are an unrelated discovery: TXA suppresses plasmin-mediated activation of melanocytes, which is particularly relevant in melasma pathogenesis.
Cestari and colleagues’ 2014 review (J Drugs Dermatol) is the foundational reference for topical and oral TXA in melasma. The evidence at the time supported topical 2-5% concentrations and oral 250-500mg twice daily. Subsequent work has refined dosing and identified responder subgroups — TXA is particularly effective for melasma with a vascular component, less so for purely pigmentary melasma.
Topical TXA at 2-3% has accumulated strong evidence for SoC melasma over the past decade. It’s now first-line in many dermatology protocols. The mechanism is aligned with melasma’s pathogenesis — not just pigment-lightening but pigmentation-driver-suppressing — which is why responses tend to be more durable than ingredients that only target tyrosinase.
Oral TXA requires medical supervision. Contraindications include thrombotic risk factors, hormonal contraception interactions, and pregnancy. It’s increasingly prescribed for refractory melasma in dermatology practice but isn’t a self-administration target.
Stacking protocols — what pairs and what conflicts
Kojic + alpha-arbutin: redundant. Both target tyrosinase. You’re not getting additive benefit from the combination — you’re getting a marketing claim. Pick one based on concentration tolerance.
Kojic + tranexamic: complementary. Different mechanisms (tyrosinase inhibition vs. plasmin/melanocyte suppression) target different points in melanogenesis. This combination has clinical support for melasma when hydroquinone is unavailable or contraindicated.
Alpha-arbutin + tranexamic: defensible for tolerance-limited patients. Same mechanism logic as the kojic-tranexamic combination but with the gentler arbutin profile.
All three stacked: usually marketing rather than clinical. The kojic-arbutin redundancy means you’re getting two ingredients competing for the same receptors with their combined irritation budget. If you’re already using TXA + one tyrosinase inhibitor, the third active is occupying formulation space without proportional clinical benefit.
Concentrations that actually work
Kojic acid: 1-2% for therapeutic use. Above 2% increases irritation without proportional benefit. Stability requires opaque packaging or stabilizer derivatives.
Alpha-arbutin: 2% is the most-evidenced concentration. The Naturium / Ordinary / Skin Inc 2% serums are reasonable starting points. 1% products are underpowered for most therapeutic goals.
Topical tranexamic acid: 2-5%. The SkinMedica Lytera 2.0 (4% TXA) and SkinCeuticals Discoloration Defense (3% TXA) are the most-evidenced commercial formulations. Below 2%, the clinical evidence is weak.
What the marketing inflates
A few patterns worth knowing.
“Up to 10% kojic” — the formulation is irritating without being more effective. Buyers usually stop using it.
“Bio-fermented arbutin” — alpha-arbutin and beta-arbutin are produced by fermentation. The “bio” prefix is descriptive of standard manufacturing, not a clinical differentiator.
“Tranexamic acid plus” — the “plus” usually means under-dosed TXA combined with a marketing-friendly secondary ingredient. Check the percentage.
“Triple-action brightener” — almost always alpha-arbutin + kojic + niacinamide. Two of the three target tyrosinase; niacinamide blocks melanosome transfer. The triple-action framing oversells what’s mostly a duplicated mechanism.
What to actually buy
For active melasma in Fitzpatrick IV-VI: 3-4% topical tranexamic acid is the highest-evidence OTC option. If oral TXA is available with medical supervision, that adds substantial additional benefit.
For acne PIH: kojic acid 2% + niacinamide 4% is well-supported and gentler than the alternatives.
For maintenance after a hydroquinone course: alpha-arbutin 2% is appropriate. The gentler profile fits long-term use, and the maintenance role doesn’t require maximum potency.
For sensitive patients who can’t tolerate hydroquinone or higher-concentration brighteners: alpha-arbutin 2% with topical TXA 2% as a rotating regimen.
FAQ
*Which is more effective for hyperpigmentation: kojic acid or arbutin?*
Kojic acid is more potent per molecule but more irritating at therapeutic concentrations. Alpha-arbutin is slower-acting but better-tolerated. For active pigment, kojic acid at 1-2% has more evidence. For maintenance or sensitive skin, alpha-arbutin at 2% is the better choice.
*Can I use kojic acid and tranexamic acid together?*
Yes. They target different points in melanogenesis — kojic inhibits tyrosinase; tranexamic suppresses plasmin-mediated melanocyte activation — and the combination has clinical support, particularly for melasma. Stack at moderate concentrations (kojic 1-2%, TXA 2-3%).
*Is oral tranexamic acid safe for melasma?*
Oral tranexamic acid is increasingly prescribed for refractory melasma at 250-500mg twice daily. It requires medical supervision because of contraindications including thrombotic risk, hormonal contraception interactions, and pregnancy. It shouldn’t be self-administered.
*What’s the right concentration of kojic acid for darker skin tones?*
1-2% is the therapeutic window. Above 2-3%, irritation becomes meaningful and can trigger PIH that net-negatives the brightening benefit in Fitzpatrick IV-VI skin.
References
- Lee S. Kojic acid: properties, derivatives and applications. J Cosmet Dermatol. 2015. PubMed.
- Boissy RE, Visscher M, DeLong MA. DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol. 2005. PubMed.
- Cestari TF, Dantas LP, Boza JC. Acquired hyperpigmentations: Tranexamic acid in the treatment of melasma. J Drugs Dermatol. 2014. PubMed.
Khabir Uddin is the founder of Elelaf Journal. This article is editorial, not medical advice. Oral tranexamic acid requires medical supervision; the rest of these protocols are appropriate for self-administration with photographic progress tracking.